Journal article
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
Abstract
This analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized (2:1) patients to receive glasdegib + LDAC (de novo, n = 38; secondary acute myeloid leukemia, n = 40) or LDAC alone (de novo, n = 18; secondary acute myeloid leukemia, n = 20). At the …
Authors
Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ
Journal
Annals of Hematology, Vol. 100, No. 5, pp. 1181–1194
Publisher
Springer Nature
Publication Date
5 2021
DOI
10.1007/s00277-021-04465-4
ISSN
0939-5555